Literature DB >> 21571164

Condyloma accuminatum treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, 18).

Hee Jung Lee, Jin Ki Kim, Dong Hyun Kim, Moon Soo Yoon.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571164     DOI: 10.1016/j.jaad.2010.12.032

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  4 in total

1.  Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.

Authors:  Richard Gilson; Diarmuid Nugent; Kate Bennett; Caroline J Doré; Macey L Murray; Jade Meadows; Lewis J Haddow; Charles Lacey; Frank Sandmann; Mark Jit; Kate Soldan; Michelle Tetlow; Emilia Caverly; Mayura Nathan; Andrew J Copas
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

2.  Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial).

Authors:  Macey L Murray; Jade Meadows; Caroline J Doré; Andrew J Copas; Lewis J Haddow; Charles Lacey; Mark Jit; Kate Soldan; Kate Bennett; Michelle Tetlow; Mayura Nathan; Richard Gilson
Journal:  BMC Med Res Methodol       Date:  2018-11-06       Impact factor: 4.615

3.  Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study.

Authors:  Hoon Choi
Journal:  Int Braz J Urol       Date:  2019 Mar-Apr       Impact factor: 3.050

Review 4.  The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease.

Authors:  Anna Rosa Garbuglia; Daniele Lapa; Catia Sias; Maria Rosaria Capobianchi; Paola Del Porto
Journal:  Front Immunol       Date:  2020-02-18       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.